Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATRANASDAQ:FBLGNASDAQ:ITRMNASDAQ:ORGS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$7.42+1.4%$6.58$5.01▼$19.00$43.47M0.32123,157 shs30,550 shsFBLGFibroBiologics$1.14-7.0%$1.06$0.76▼$13.59$42.83M0.16290,629 shs162,250 shsITRMIterum Therapeutics$1.26$1.28$0.81▼$3.02$43.57M2.87983,467 shs261,546 shsORGSOrgenesis$2.32+0.2%$2.81$0.87▼$10.80$11.13M0.910,952 shs1,817 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics+1.37%+20.85%+13.63%-11.24%-56.99%FBLGFibroBiologics-6.97%-17.75%+19.47%-28.62%-88.77%ITRMIterum Therapeutics0.00%+22.33%0.00%-15.44%-24.55%ORGSOrgenesis+0.22%-6.45%-31.16%+71.85%+231,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATRAAtara Biotherapeutics4.0321 of 5 stars3.32.00.04.72.42.50.6FBLGFibroBiologics2.9193 of 5 stars3.63.00.00.03.61.70.6ITRMIterum Therapeutics2.5828 of 5 stars3.55.00.00.03.60.00.0ORGSOrgenesisN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics 2.57Moderate Buy$17.75139.22% UpsideFBLGFibroBiologics 3.20Buy$13.001,045.37% UpsideITRMIterum Therapeutics 3.00Buy$5.00296.83% UpsideORGSOrgenesis 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ORGS, ITRM, ATRA, and FBLG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/1/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/1/2025FBLGFibroBiologicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/11/2025ATRAAtara BiotherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.002/27/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.002/13/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.002/13/2025FBLGFibroBiologicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$128.94M0.34N/AN/A($24.34) per share-0.30FBLGFibroBiologicsN/AN/AN/AN/A$0.04 per shareN/AITRMIterum TherapeuticsN/AN/AN/AN/A($0.12) per shareN/AORGSOrgenesis$662K16.82N/AN/A($6.58) per share-0.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics-$276.13M-$12.97N/AN/AN/A-132.58%N/A-90.16%5/8/2025 (Estimated)FBLGFibroBiologics-$16.49M-$0.34N/AN/AN/AN/AN/A-225.34%5/13/2025 (Estimated)ITRMIterum Therapeutics-$24.77M-$1.31N/A∞N/AN/AN/A-90.85%5/12/2025 (Estimated)ORGSOrgenesis-$55.36MN/A0.00∞N/A-3,827.81%N/A-130.18%N/ALatest ORGS, ITRM, ATRA, and FBLG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025N/AFBLGFibroBiologics-$0.10N/AN/AN/AN/AN/A5/12/2025Q1 2025ITRMIterum Therapeutics-$0.23N/AN/AN/AN/AN/A5/8/2025Q1 2025ATRAAtara Biotherapeutics-$3.07N/AN/AN/A$4.30 millionN/A3/31/2025Q4 2024FBLGFibroBiologics-$0.10-$0.09+$0.01-$0.09N/AN/A3/7/2025Q4 2024ATRAAtara Biotherapeutics-$3.82-$1.19+$2.63-$1.19$20.58 million$32.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AFBLGFibroBiologicsN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/AORGSOrgenesisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A0.590.50FBLGFibroBiologicsN/A1.231.23ITRMIterum TherapeuticsN/A1.411.41ORGSOrgenesisN/A0.070.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%FBLGFibroBiologicsN/AITRMIterum Therapeutics9.21%ORGSOrgenesis22.56%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics3.70%FBLGFibroBiologics20.80%ITRMIterum Therapeutics9.20%ORGSOrgenesis5.66%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics3305.86 million5.55 millionOptionableFBLGFibroBiologics1037.74 million28.84 millionN/AITRMIterum Therapeutics1034.58 million31.40 millionNot OptionableORGSOrgenesis1504.80 million4.53 millionOptionableORGS, ITRM, ATRA, and FBLG HeadlinesRecent News About These CompaniesOrgenesis (NASDAQ:ORGS) Trading 2% Higher - Should You Buy?April 26 at 2:55 AM | americanbankingnews.comOrgenesis Delays 10-K Filing Amid Financial ChallengesApril 1, 2025 | tipranks.comOrgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury TherapiesMarch 6, 2025 | accessnewswire.comOrgenesis Inc. (ORGS) Stock Price, News, Quote & History - Yahoo FinanceFebruary 9, 2025 | finance.yahoo.comOrgenesis secures $5M equity investment from Williamsburg VentureJanuary 29, 2025 | markets.businessinsider.comOrgenesis Inc: Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture HoldingsJanuary 28, 2025 | finanznachrichten.deOrgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture HoldingsJanuary 28, 2025 | accessnewswire.comOrgenesis Inc. Reports Q3 2024 Financial ResultsNovember 15, 2024 | markets.businessinsider.comOrgenesis Provides Third Quarter 2024 Business UpdateNovember 13, 2024 | markets.businessinsider.comOrgenesis Expands Board with Three New AppointmentsNovember 3, 2024 | markets.businessinsider.comOrgenesis commences trading on OTCQX Best MarketOctober 22, 2024 | markets.businessinsider.comOrgenesis Commences Trading on OTCQX® Best MarketOctober 21, 2024 | markets.businessinsider.comOrgenesis (NASDAQ:ORGS) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.com45O.SG,0P0001J8IU,0 (45O.SG)September 24, 2024 | au.finance.yahoo.comWhy Orgenesis (ORGS) Stock Is Down 23% TodaySeptember 24, 2024 | msn.comOrgenesis Inc.: Orgenesis Announces Reverse Stock SplitSeptember 23, 2024 | finanznachrichten.deOrgenesis Approves 1-for-10 Reverse Stock SplitSeptember 23, 2024 | markets.businessinsider.comOrgenesis Announces Reverse Stock SplitSeptember 23, 2024 | markets.businessinsider.comIs Orgenesis Stock (ORGS) a Good Investment?September 19, 2024 | aaii.comOrgenesis Advancing CD19 CAR T-cell Therapy Into Phase I/II Leukemia TrialAugust 31, 2024 | precisionmedicineonline.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeORGS, ITRM, ATRA, and FBLG Company DescriptionsAtara Biotherapeutics NASDAQ:ATRA$7.42 +0.10 (+1.37%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$5.80 -1.62 (-21.83%) As of 04:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.FibroBiologics NASDAQ:FBLG$1.14 -0.09 (-6.97%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$1.15 +0.02 (+1.67%) As of 04/28/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.Iterum Therapeutics NASDAQ:ITRM$1.26 0.00 (0.00%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$1.25 -0.01 (-0.40%) As of 04:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Orgenesis NASDAQ:ORGS$2.32 +0.01 (+0.22%) As of 04/28/2025 03:03 PM EasternOrgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Rebounds After Strong Earnings and Buyback Announcement Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? The Bear Market Has Only Just Started - Here's Why MarketBeat Week in Review – 04/21 - 04/25 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S. PepsiCo’s Stock Price is Disconnected From Reality: Time to Buy Bears Can Reap Big Benefits With These 3 Short ETF Bets Why Institutions Are Buying Super Micro Computer Stock Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
